Form 4: Intuitive Surgical EVP Mark Brosius Executes Stock Sale

Intuitive Surgical EVP Mark Brosius sold 54 shares of common stock across three transactions under a Rule 10b5-1 trading plan.

Summary

• Mark Brosius, EVP & Chief Manufacturing and Supply Chain Officer at Intuitive Surgical, sold a total of 54 shares of common stock.
• The sales occurred on May 18, 19, and 20, 2026, in three equal tranches of 18 shares each.
• The shares were sold at prices ranging from $422.47 to $440.70 per share.
• Following these transactions, the reporting person retains beneficial ownership of 1,559 shares of common stock.
• The transactions were executed pursuant to a pre-established Rule 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales were executed under a pre-planned, automated trading arrangement.

Positives

• The transactions were conducted under a pre-planned Rule 10b5-1 trading plan, which is designed to avoid concerns regarding insider trading.

Negatives

• The filing reflects a reduction in the executive's direct equity stake in the company.

Risks

• None identified; this is a routine disclosure of executive stock transactions.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine executive stock sales under 10b5-1 plans are standard corporate practice and generally do not signal a change in company fundamentals or management sentiment.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives at large-cap medical device companies like Medtronic or Stryker to manage equity holdings without triggering market concerns.

Stakeholder Impact

• Minimal impact on shareholders as the transaction volume is negligible relative to the total outstanding shares of Intuitive Surgical.

Next Steps

• Continued monitoring of future Form 4 filings for further transactions under the existing 10b5-1 plan.

Key Dates

Keywords

Intuitive Surgical, ISRG, Insider Trading, Form 4, Stock Sale, Executive Compensation